|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, Israel
2 Department of Organic Chemistry, The Weizmann Institute of Science, Israel
3 Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel
4 Biological Chemistry, Hebrew University, Jerusalem, Israel
* To whom correspondence should be addressed. E-mail: ioav{at}cc.huji.ac.il.
Non transferrin-bound iron, commonly found in the plasma of iron-overloaded individuals permeates into cells via pathways independent of the transferrin receptor. This may lead to excessive cellular accumulation of labile iron followed by oxidative damage and eventually organ failure. Mitochondria are the principal destination of iron in cells and a primary site of pro-oxidant generation, yet their mode of acquisition of iron is poorly understood. Using fluorescent probes sensitive to iron or to reactive oxygen species, targeted to cytosol and/or to mitochondria, we traced the ingress of labile iron into these compartments by fluorescence microscopy and quantitative fluorimetry. We observed that: a. penetration of non-transferrin bound iron into the cytosol and subsequently into mitochondria occurs with barely detectable delay and b. loading of the cytosol with high-affinity iron-binding chelators does not abrogate iron uptake into mitochondria. Therefore, a fraction of non-transferrin bound iron acquired by cells reaches the mitochondria in a non-labile form. The physiologic role of occluded iron transfer might be to confer cells with a "safe and efficient cytosolic iron corridor" to mitochondria. However, such a mechanism might be deleterious in iron overload conditions, as it could lead to surplus accumulation of iron in these critical organelles.
This article has been cited by other articles:
![]() |
Y.-S. Sohn, W. Breuer, A. Munnich, and Z. I. Cabantchik Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications Blood, February 1, 2008; 111(3): 1690 - 1699. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |